SCHEMBL15218458

SCHEMBL15218458

CS(=O)(=O)N1CCC(F)(F)CC1

nearest known ligand 0.50

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 11/20 0.50
SMN1; SMN2 Q16637 2/20 0.50
CYP2C19 P33261 5/20 0.44
NEK2 P51955 1/20 0.44
CYP2C9 P11712 5/20 0.43
CYP3A4 P08684 5/20 0.42
HSD17B10 Q99714 4/20 0.42
ALDH1A1 P00352 4/20 0.42
CYP1A2 P05177 3/20 0.42
HIF1A Q16665 2/20 0.42
USP2 O75604 2/20 0.42
HPGD P15428 2/20 0.42
TSHR P16473 2/20 0.41
MEN1 O00255 3/20 0.39
KMT2A Q03164 3/20 0.39
ALOX15 P16050 1/20 0.39
KDM1A O60341 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13929775 0.86 CYP2D6 (0.43) CYP2D6SMN1; SMN2CYP2C19NEK2CYP2C9
SCHEMBL25723117 0.83 CYP2D6 (0.44) CYP2D6SMN1; SMN2CYP2C19NEK2CYP2C9
SCHEMBL18400630 0.78 POLB (0.41) CYP2D6SMN1; SMN2HSD17B10ALDH1A1TSHR
SCHEMBL28546228 0.78 CYP2D6 (0.41) CYP2D6SMN1; SMN2CYP2C19NEK2CYP2C9
SCHEMBL25626550 0.78 CYP2D6 (0.53) CYP2D6SMN1; SMN2CYP2C19NEK2CYP2C9
SCHEMBL1025135 0.77 CA1 (0.48) CYP2D6SMN1; SMN2
SCHEMBL7603407 0.77 CYP2D6 (0.47) CYP2D6SMN1; SMN2CYP2C19NEK2CYP2C9
SCHEMBL9991833 0.77 CNR1 (0.32) CYP2D6SMN1; SMN2
SCHEMBL12895012 0.76 CYP2D6 (0.56) CYP2D6SMN1; SMN2CYP2C19NEK2CYP2C9
SCHEMBL17507855 0.76 CYP2D6 (0.43) CYP2D6SMN1; SMN2CYP2C19NEK2CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4006028-A1 IRAK4 KINASE INHIBITOR AND PREPARATION METHOD THEREFOR Zhuhai Yufan Biotechnologies Co., Ltd (CN) 2022-06-01 EP disclosed
US-20220119429-A1 FLUORINE-CONTAINING COMPOUND AND ANTI-CANCER MEDICAL USE THEREOF ASCENTAWITS PHARMACEUTICALS, LTD. (CN) 2022-04-21 US disclosed
WO-2020228685-A9 FLUORINE-CONTAINING COMPOUND AND ANTI-CANCER MEDICAL USE THEREOF 深圳艾欣达伟医药科技有限公司 2021-02-18 WO disclosed
WO-2020228685-A1 FLUORINE-CONTAINING COMPOUND AND ANTI-CANCER MEDICAL USE THEREOF 深圳艾欣达伟医药科技有限公司 2020-11-19 WO disclosed
US-9867806-B2 Compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis GALAPAGOS NV (BE) 2018-01-16 US disclosed
US-20160313639-A1 PHOTOSENSITIVE RESIN COMPOSITION, PIXEL LAYER, PROTECTIVE FILM, SPACER, THIN-FILM TRANSISTOR, COLOR FILTER, AND LIQUID CRYSTAL DISPLAY APPARATUS CHI MEI CORPORATION (TW) 2016-10-27 US disclosed
EP-2671582-B1 RING-FUSED HETEROCYCLIC DERIVATIVE KYOWA HAKKO KIRIN CO LTD (JP) 2016-07-13 EP disclosed
US-9274419-B2 Blue photosensitive resin composition for color filter and application thereof CHI MEI CORPORATION (TW) 2016-03-01 US disclosed
US-20150268554-A1 BLUE PHOTOSENSITIVE RESIN COMPOSITION FOR COLOR FILTER AND APPLICATION THEREOF CHI MEI CORPORATION (TW) 2015-09-24 US disclosed
US-9086532-B2 Blue photosensitive resin composition for color filter and uses thereof CHI MEI CORPORATION (TW) 2015-07-21 US disclosed
US-9081142-B2 Photosensitive resin composition for a color filter and uses thereof CHI MEI CORPORATION (TW) 2015-07-14 US disclosed
US-9000186-B2 Ring-fused heterocyclic derivative KYOWA HAKKO KIRIN CO., LTD. (JP) 2015-04-07 US disclosed
US-9000186-B2 Ring-fused heterocyclic derivative KYOWA HAKKO KIRIN CO., LTD. (JP) 2015-04-07 US disclosed
US-20150042931-A1 BLUE PHOTOSENSITIVE RESIN COMPOSITION FOR COLOR FILTER AND USES THEREOF CHI MEI CORPORATION (TW) 2015-02-12 US disclosed
US-20150042931-A1 BLUE PHOTOSENSITIVE RESIN COMPOSITION FOR COLOR FILTER AND USES THEREOF CHI MEI CORPORATION (TW) 2015-02-12 US disclosed
US-20140346416-A1 PHOTOSENSITIVE RESIN COMPOSITION FOR A COLOR FILTER AND USES THEREOF CHI MEI CORPORATION (TW) 2014-11-27 US disclosed
US-20140346416-A1 PHOTOSENSITIVE RESIN COMPOSITION FOR A COLOR FILTER AND USES THEREOF CHI MEI CORPORATION (TW) 2014-11-27 US disclosed
US-20140038941-A1 RING-FUSED HETEROCYCLIC DERIVATIVE KYOWA HAKKO KIRIN CO., LTD. (JP) 2014-02-06 US disclosed
US-20140038941-A1 RING-FUSED HETEROCYCLIC DERIVATIVE KYOWA HAKKO KIRIN CO., LTD. (JP) 2014-02-06 US disclosed
US-20130222738-A1 COLOR LIQUID CRYSTAL DISPLAY DEVICE CHI MEI CORPORATION (TW) 2013-08-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220119429-A1 FLUORINE-CONTAINING COMPOUND AND ANTI-CANCER MEDICAL USE THEREOF FLI1, FOLR2, FOLR1 CYP2D6 446/4885SMN1; SMN2 3609/4885CYP2C19 382/4885
US-20140038941-A1 RING-FUSED HETEROCYCLIC DERIVATIVE CACNA1E, SLC8A1, CALCR CYP2D6 2044/4885SMN1; SMN2 4334/4885CYP2C19 1422/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.